{'fraction_non_alphanumeric': 0.017172295363480253, 'fraction_numerical': 0.008586147681740127, 'mean_word_length': 5.828125, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The relationship between nonalcoholic fatty liver disease and cancers

Objectives To discuss the link age between nonalcoholic fatty hepatic disease and malignant tumors. Data sources MEDLINE databases (PubMed, Medscape, Science Direct) and every one material obtainable on the net from 1998 to 2019 were searched. Study selection The initial search included 88 articles, of that 34 met the inclusion criteria. The articles studied the linkage between nonalcoholic fatty hepatic disease and malignant tumors. Data extraction If the studies failed to fulfill the inclusion criteria, they were excluded. Study quality assessment enclosed whether or not moral approval was gained, eligibility criteria nominative, applicable controls and adequate data, and outlined assessment measures. Data synthesis Comparisons were created by structured review with the results tabulated. Findings In total 23 probably relevant publications were enclosed. The studies indicated that nonalcoholic fatty hepatic disease plays an important role in development of different types of malignant tumors, including hepatocellular carcinoma, colorectal carcinoma, and prostate cancer. Conclusion Nonalcoholic fatty liver disease (NAFLD) is a complicated multifactorial disease closely interrelated with obesity and type 2 diabetes, and shares with them a significant enhanced risk of several types of malignant tumors. Further studies are necessary to better define patients with high-risk NAFLD and effective screening strategies, but we encourage health care providers taking care of patients with NAFLD to be vigilant for any signs and symptoms of cancer, particularly hepatocellular and colorectal cancers, and refer the patients for further assessment and management.